bioRxiv · 10.1101/2020.05.30.125856
Sofosbuvir protects human brain organoids against SARS-CoV-2
Abstract
COVID-19 was rapidly declared a pandemic by the World Health Organization, only three months after the initial outbreak in Wuhan, China. Early clinical care mainly focused on respiratory illnesses. However, a variety of neurological manifestations in both adults and newborns are also emerging. To determine whether SARS-CoV-2 could target the human brain, we infected iPSC-derived human brain organoids. Our findings show that SARS-CoV-2 was able to infect and kill neural cells, including cortical neurons. This phenotype was accompanied by impaired synaptogenesis. Finally, Sofosbuvir, an FDA-approved antiviral drug, was able to rescue these alterations. Given that there are currently no vaccine or antiviral treatments available, urgent therapies are needed. Our findings put Sofosbuvir forward as a potential treatment to alleviate COVID-19-related neurological symptoms. One Sentence SummarySARS-CoV-2 infection causes neuronal death and impaired synaptogenesis, both rescued by Sofosbuvir treatment.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mesci, P., Macia, A., Saleh, A., Martin-Sancho, L., YIN, X., Snethlage, C., Avansini, S., Chanda, S., Muotri, A.. 2020-05-31. Sofosbuvir protects human brain organoids against SARS-CoV-2. https://doi.org/10.1101/2020.05.30.125856
Cite the original work for its findings. Save a collection to share your selection of sources.